Study shows nepafenac improves outcomes after cataract surgery in patients with diabetic retinopathy

TORONTO — Nepafenac ophthalmic suspension 0.1% demonstrated improved outcomes compared with vehicle in preventing macular edema following cataract surgery in patients with diabetic retinopathy, a presenter said.Cystoid macular edema is a common cause of poor visual outcome following uneventful cataract surgery, Rishi P. Singh, MD, said at the American Society of Retina Specialists meeting, and postsurgical macular changes are more likely to occur in patients with preexisting retinopathies.“CME can occur in up to 35% of patients who have diabetic retinopathy who undergo uncomplicated surgery,” Singh said.

Full Story →